Time: 11:00 a.m.
Place: NIH, Rockledge 2, Room 5198, Telephone Conference.
Contact Person: Dr. Michael Micklin, Scientific Review Administrator, 6701 Rockledge Drive, Room 5198, Bethesda, Maryland 20892, (301) 435–1258.

Name of SEP: Biological and Physiological Sciences.
Date: December 8, 1997.
Time: 10:00 a.m.
Place: NIH, Rockledge 2, Room 5202, Telephone Conference.
Contact Person: Dr. Anita Sostek, Scientific Review Administrator, 6701 Rockledge Drive, Room 5202, Bethesda, Maryland 20892, (301) 435–1260.

Name of SEP: Biological and Physiological Sciences.
Date: December 10, 1997.
Time: 1:00 p.m.
Place: NIH, Rockledge 2, Room 4208, Telephone Conference.
Contact Person: Dr. Anita Weinblatt, Scientific Review Administrator, 6701 Rockledge Drive, Room 4208, Bethesda, Maryland 20892, (301) 435–1224.

Name of SEP: Clinical Sciences.
Date: December 10, 1997.
Time: 1:00 p.m.
Place: NIH, Rockledge 2, Room 4112, Telephone Conference.
Contact Person: Dr. Gopal Sharma, Scientific Review Administrator, 6701 Rockledge Drive, Room 4112, Bethesda, Maryland 20892, (301) 435–1783.

Name of SEP: Clinical Sciences.
Date: December 11, 1997.
Time: 11:00 a.m.
Place: NIH, Rockledge 2, Room 4138, Telephone Conference.
Contact Person: Dr. Anthony Chung, Scientific Review Administrator, 6701 Rockledge Drive, Room 4138, Bethesda, Maryland 20892, (301) 435–1213.

Name of SEP: Biological and Physiological Sciences.
Date: December 11, 1997.
Time: 1:00 p.m.
Place: NIH, Rockledge 2, Room 4202, Telephone Conference.
Contact Person: Dr. Gene Zimmerman, Scientific Review Administrator, 6701 Rockledge Drive, Room 4202, Bethesda, Maryland 20892, (301) 435–1220.

Name of SEP: Biological and Physiological Sciences.
Date: December 11, 1997.
Time: 1:00 p.m.
Place: NIH, Rockledge 2, Room 4208, Telephone Conference.
Contact Person: Dr. Anita Weinblatt, Scientific Review Administrator, 6701 Rockledge Drive, Room 4208, Bethesda, Maryland 20892, (301) 435–1224.

Name of SEP: Chemistry and Related Sciences.
Date: December 11, 1997.
Time: 12:00 p.m.
Place: NIH, Rockledge 2, Room 4172, Telephone Conference.
Contact Person: Dr. Donald Schneider, Scientific Review Administrator, 6701 Rockledge Drive, Room 4172, Bethesda, Maryland 20892, (301) 435–1727.

Name of SEP: Biological and Physiological Sciences.
Date: December 18, 1997.
Time: 9:00 a.m.
Place: NIH, Rockledge 2, Room 5196, Telephone Conference.
Contact Person: Ms. Carol Campbell, Scientific Review Administrator, 6701 Rockledge Drive, Room 5196, Bethesda, Maryland 20892, (301) 435–1257.
Purpose/Agenda: To review Small Business Innovation Research.

Name of SEP: Microbiological and Immunological Sciences.
Date: November 21, 1997.
Time: 1:00 p.m.
Place: Doubletree Hotel, Rockville, MD.
Contact Person: Dr. Gilbert Meir, Scientific Review Administrator, 6701 Rockledge Drive, Room 5112, Bethesda, Maryland 20892, (301) 455–1169.

The notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

Name of SEP: Behavioral and Neurosciences.
Date: December 2, 1997.
Time: 8:30 a.m.
Place: Holiday Inn, Silver Spring, MD.
Contact Person: Dr. Leonard Jakubczak, Scientific Review Administrator, 6701 Rockledge Drive, Room 5172, Bethesda, Maryland 20892, (301) 435–1247.

Name of SEP: Microbiological and Immunological Sciences.
Date: December 2, 1997.
Time: 8:30 a.m.
Place: Holiday Inn, Chevy Chase, MD.
Contact Person: Dr. Gilbert Meier, Scientific Review Administrator, 6701 Rockledge Drive, Room 5112, Bethesda, Maryland 20892, (301) 435–1219.

Name of SEP: Microbiological and Immunological Sciences.
Date: December 3, 1997.
Time: 2:00 p.m.
Place: NIH, Rockledge 2, Room 5112, Telephone Conference.
Contact Person: Dr. Gilbert Meier, Scientific Review Administrator, 6701 Rockledge Drive, Room 5112, Bethesda, Maryland 20892, (301) 435–1219.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(b), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93,893, National Institutes of Health, HHS)

Dated: November 18, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–30930 Filed 11–24–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Pigment Epithelium Derived Growth Factor

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(I), announces that the National Institutes of Health is contemplating the grant of an exclusive world-wide license to GenVec, Inc., a Delaware corporation headquartered in Rockville, Maryland to practice the inventions embodied in the U.S. Patent Applications listed below (and corresponding foreign patent applications) in the field of ocular gene therapy. These inventions are owned by the Government of the United States of America as represented by the Department of Health and Human Services.

1. USSN 07/952,796 entitled ''DNA Clones for the Expression of Pigment Epithelium Derived Growth Factor and Related Proteins'' filed September 24, 1992 by Fintan R. Steele, Gerald J. Chader, Joyce Tombran-Tink and Sofia P. Becerra.

2. USSN 08/257,963 entitled ''Pigment Epithelium Derived Factor: Characterizations of Its Biological Activity and Sequences Encoding and Expressing the Protein'' filed June 7, 1994 by Gerald J. Chader, Sofia P. Becerra, Joan P. Schwartz, Takayuki Taniwaki and Yukihera Sugita.

3. USSN 08/279,979 entitled ''Retinal Pigmented Epithelium Derived Neurotrophic Factor'' filed July 25, 1994 by Fintan R. Steele, Gerald J. Chader, Joyce Tombran-Tink, Sofia P. Becerra and Ignacio R. Rodriquez and Lincoln Johnson.

4. USSN 08/367,841 entitled ''Pigment Epithelium Derived Factor: Characterization, Genomic Organization and Sequence of the PEDF Gene'' filed December 30, 1994 by Gerald J. Chader, Joyce Tombran-Tink, Sofia P. Becerra, Ignacio R. Rodriquez and Fintan R. Steele and Lincoln Johnson.

5. USSN 08/377,710 entitled ''DNA Clones for the Expression of Pigment Epithelium Derived Factor and Related Proteins'' filed January 25, 1995 by Fintan R. Steele, Gerald L. Chader, Joyce Tombran-Tink, Sofia P. Becerra and Ignacio R. Rodriquez.

6. USSN 08/520,373 entitled ''Retinal Pigmented Epithelium Derived

Neurotrophic Factor'' filed August 29, 1995 by Gerald J. Chader, Joyce Tombran-Tink, Sofia P. Becerra, Ignacio R. Rodriquez and Fintan R. Steele.

DATES: Only written comments and/or applications for a license which are received by NIH on or before January 26, 1998 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Jaconda Wagner, Esq., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; *Telephone:* (301) 496–7735 ext. 284; *Facsimile:* (301) 402–0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Cultured retinal pigment epithelium (RPE) cells secrete pigment epithelium-derived factor (PEDF) into the photoreceptor matrix. This protein, with a molecular weight of approximately 50 kD, has trophic activity which induces neuronal cell differentiation, survival of mature neurons and a gliastatic effect. This technology can be used to develop therapeutics for the treatment of inflammatory, vascular, degenerative and dystrophic diseases of the retina and central nervous system (CNS) as well as to treat cancers of the CNS and conditions resulting from the activity of serine proteases.

The various patent applications encompassing this invention contain claims to a recombinant DNA molecule comprising a gene encoding the PEDF; an organism transformed with the recombinant DNA molecule; a method of treating tumors ocular diseases, nerve injuries and conditions resulting from the activity of serine proteases using the PEDF; the PEDF protein and its biological activity, specifically a method of enhancing neuron cell survival and inhibiting glial cell proliferation; purified antibodies to PEDF; a method for purifying the PEDF; and immunoassay for detecting the level of PEDF in a sample.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated licenses. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: November 14, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97–30924 Filed 11–24–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4263–N–58]

Notice of Proposed Information Collection for Public Comment

AGENCY: Office of the Assistant Secretary for Policy Development and Research, HUD.

ACTION: Notice.

SUMMARY: The proposed collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: Comments due: January 26, 1998.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Reports Liaison Officer, Policy Development & Research, Department of Housing & Urban Development, 451—7th Street, SW, Room 8228, Washington, DC 20410.

FOR FURTHER INFORMATION CONTACT: Alan Rothman, Social Science Research Analyst, Office of Policy Development and Research—telephone (202) 708–4370, x139 (this is not a toll-free number) for copies of the proposed forms and other available documents.

SUPPLEMENTARY INFORMATION: The Department will submit the proposed information collection to OMB for review, as required by the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended).

The office is soliciting comments from members of the public and affected agencies concerning the proposed collection of information to: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

This notice also lists the following information:

Title of Proposal: Assessment and Analysis of Multifamily Building's Conformity with Fair Housing Guidelines Provisions

OMB Control Number: None.

Description of the Need for Information and the Proposed Use: The Fair Housing Amendment Act (the Act) of 1988 requires that newly constructed multifamily dwellings covered under the Act, available for first occupancy after March 13, 1991, be designated and constructed to be accessible to persons with disabilities. The purpose of this project is to assess the extent of conformity with the accessibility provisions and examine reasons for, as well as explanations, for different patterns of conformity/non-conformity.

Agency Form Numbers: Not applicable.

Members of the Affected Public: Property owners, property management personnel, occupants, local code officials, architects, engineers, and builders.

Estimation of the Total Number of Hours Needed to Prepare the Information Collection Including Number of Respondents, Frequency of Response, and Hours of Response: Grand total hours for all personnel is 11,936 labor hours over ninety (90) weeks. Total hours for contractor personnel is estimated at 10,900 hours. The total hours for voluntary one-time responses, from management/owners/project representatives and residents, is 1,036 hours for the 386 projects to be considered in the statistical model. The hour breakdown for the survey respondents is 128 hours during the mobilization phase, 803 hours during Phase I—survey/data gathering efforts, and 105 hours for Phase II—assessment and analysis effort.

Status of the Proposed Information Collection: Pending OMB approval.

Authority: Section 3506 of the Paperwork Reduction Act of 1995, 44 U.S.C. Chapter 35, as amended.